According to the Centers for Disease Control and Prevention (CDC), in 2019, approximately 12% of adults in the United States aged 18 and older reported having a mobility disability that made it difficult or impossible for them to walk. This equates to millions of individuals who rely on wheelchairs or other aids for their daily mobility.
SAAR Inc. (Skeletal Axes Assistive Robots) aims to develop and market a range of patented lower extremity exoskeleton products that enable individuals with mobility impairments to walk again.
Established in 2022 by a team of entrepreneurs with extensive experience in developing high-precision, high-velocity articulating and cartesian automation systems for various industries, including military, automotive, semiconductor, electronics, and medical sectors, we are leveraging our expertise in motion control to assist individuals who have lost their ability to walk due to paralysis-inducing diseases or spinal cord injuries.
Exoskeletons have been in use to aid the disabled and enable them to walk, using traditional motion controllers that work on the PID concept, a closed loop system that has three parameters to base movement on. While these devices can help disabled folks move around, they're limited in their ability to work in a random and unpredicted environment, like when attached to a person.
Our exoskeleton products however will utilize reinforcement learning for motion control and supervised learning for other key features, to provide a safe and highly capable device to enable mobility for the users.
The challenge of adopting this relatively new technology to medical exoskeletons, which have great needs to millions of handicapped immobilized people, such as the elderly, paralyzed with spinal cord injuries and multiple sclerosis, was the driving force of SAAR Inc. founders in becoming the world leaders in AI / ML exoskeletons.
Our vision was to launch with two patented products using self-funding and private investors, with the goal of expanding globally and eventually listing on the Nasdaq within 5 years. The first product, RoboChair, priced between $3,000 and $10,000, is a single-axis exoskeleton designed for use as both exercise equipment and a Sit-to-Stand assist device for elderly and limited mobility users. This product is currently getting ready for the beta testing phase at assisted living facilities. Our main product, Exollent, priced between $60,000 and $100,000, is a multi-axis autonomous robot intended to provide mobility assistance, including gait, step climbing, and Sit-to-Stand functionality, with or without the RoboChair, for individuals with disabilities.
All of our products are based on standard mechatronics robots with custom control options including Bang/Bang ( simple on/off), PID (most common with known motion profile ), and AI/ML (most powerful in random nonlinear environment). They're also paired with a mobile app that allows doctors and physical therapists to create custom exercise routines for the users to follow, that tracks their progress and using supervised learning optimizes those routines to help speed up recovery where possible.
Below is our revenue model and revenue stream as planned for the product lines.
Revenue model
- Transactional for products sold.
- Subscription model
- Personalized rehabilitation/recovery routines
- Recovery progress monitoring
- Patient performance Insights
- Service based for product maintenance.
- Technology licensing
Revenue Stream
- Sales through Medical Products Distributors
- Physical therapy and rehabilitation centers
- Hospitals
- Retirement homes
- Direct to Patient sales / custom solutions
- Health Insurance
- Medicaid
- VA
- Subscription service
Our founder team includes CEO, COB/CIO, CFO & CTO with partner team that includes a PhD. Physical Therapist at a VA facility, Mechanical Engineer, Electrical Engineer, Sales & Marketing lead and Technical Support lead. Academic partners include a System Analyst and Computer Science resource.
We're searching for investors to fund our next set of activities in the following phases:
Phase 1 seeking $100K investment
- Complete Beta testing for RoboChair and redesign for manufacturability
Phase 2 seeking $1M investment for one year
- Complete Exollent prototype with RL motion controller and complete Beta testing
- Redesign for manufacturability including RL motion controller
- Set up manufacturing/assembly facility for production of two product lines for US market.
Phase 3 seeking additional $4M over 4 years
- Ramp up manufacturing with increase in US sales
- Expand to international markets and go public after 5 years.
We recognize this is an ambitious plan, however we feel the current team contains the right resources to get us started and grow the company to hit our target IPO in our fifth year after funding.
Join us in revolutionizing a handicapped persons dream, to be able to walk again!